SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • January 3rd, 2020 • Onconova Therapeutics, Inc. • Pharmaceutical preparations • New York
Contract Type FiledJanuary 3rd, 2020 Company Industry JurisdictionThis Securities Purchase Agreement (this “Agreement”) is dated as of December 31, 2019, between Onconova Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT ONCONOVA THERAPEUTICS, INC.Onconova Therapeutics, Inc. • January 3rd, 2020 • Pharmaceutical preparations
Company FiledJanuary 3rd, 2020 IndustryTHIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on January 3, 2024 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Onconova Therapeutics, Inc., a Delaware corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This warrant is being issued pursuant to that certain engagement letter, dated as of December 6, 2019, by and between the Company and H.C. Wainwright & Co., LLC.